Conditions: Type 2 Diabetes Mellitus
Keywords: diabetes exenatide once weekly Byetta sitagliptin Januvia thiazolidinedione Amylin Lilly Pioglitazone
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 514
Healthy volunteers: no

Brief summary:
This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will also be compared.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: exenatide once weekly intervention 2: sitagliptin intervention 3: pioglitazone intervention 4: placebo tablet intervention 5: placebo once weekly
Intervention descriptions: intervention 1: subcutaneous injection, 2.0mg, once a week intervention 2: oral tablet, 100mg, once a day intervention 3: oral tablet, 45mg, once a day intervention 4: oral tablet, once a day intervention 5: subcutaneous injection, once a week

Protocol document: